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Abstract
HIV-1 infection can trigger acute episodes of Idiopathic Thrombocytoponic Purpura (ITP), and Thrombotic
Thrombocytopenic Purpura (TTP), particularly in populations with advanced disease and poor adherence to
antiretroviral therapy (ART). These diseases should be distinguished because they respond to different treatments.
Previous studies done in adults with HIV-TTP have recommended the prompt initiation or re-initiation of ART in parallel
with plasma exchange therapy to improve the clinical outcome of these patients. Here, we describe a case of HIVTTP resulting in an acute hemorrhagic stroke in a 16 year old female with perinatally acquired HIV infection and
non-adherence to ART, who presented with severe thrombocytopenia, microangiopathic hemolytic anemia, and a
past medical history of HIV-ITP. Both differential diagnosis and treatments for HIV-ITP and HIV-TTP were considered
simultaneously. A decrease in plasma ADAMTS13 activity (<5%) without detectable inhibitory antibodies confirmed
the diagnosis of HIV-TTP. Re-initiation of ART and plasma exchange resulted in a marked decrease in the HIV-RNA
viral load, recovery of the platelet count, and complete recovery was achieved with sustained virologic suppression.

Keywords: HIV-TTP; Hemorrhagic stroke; HIV-ITP; HIV-HUS;
Microangiopathic hemolytic anemia; Immune thrombocytopenic
purpura; Antiretroviral therapy; Plasma exchange

Introduction
Several hematologic complications such as anemia,
thrombocytopenia, neutropenia, and coagulopathy caused by direct or
indirect effects of HIV-1 have been reported in HIV-infected children
[1]. HIV-1 can trigger acute and lethal atypical episodes of the Hemolytic
Uremic Syndrome (HUS) [2,3], and Thrombotic Thrombocytopenic
Purpura (TTP) [4-8]. The main histological feature of HIV-associated
HUS or TTP is microvascular thrombosis with endothelial damage,
affecting predominately the kidney and brain, and potentially other
tissues as well [2-9].
Classic TTP results from the deficiency or malfunction of a
desintegrin and metalloproteinase with a thrombospondin type 1
motif, member 13 (ADAMTS13), which fails to cleave the ultralarge
multimers of the von-Willebrand factor (v-WF) that are released by
endothelial cells [10]. In contrast, HUS and other HIV-hematological
complications that mimic the clinical features of TTP, including
Immune Thrombocytopenic Purpura (ITP), are triggered by different
immunological or infectious mechanisms [3-8]. Importantly, effective
antiretroviral treatments decrease all HIV-associated hematologic comorbidities, including HUS, TTP, and ITP underlying a unique role of
the virus and the cytokines released by infected cells in the pathogenesis
of these diseases [11,12]. Despite the overall progress made in the
treatment of HIV-infection, HIV- infected children continue to be at
high risk of developing severe cases of HUS and TTP, particularly in
populations for whom treatment is not available or adherence is poor
[2-7]. Nonetheless, very little information is available to guide the
treatment of these children. Here, we describe a case of TTP in a 16
year old female with perinatally acquired HIV-infection who presented
with severe thrombocytopenia, microangiopathic hemolytic anemia
(MAHA), and a past medical history of HIV-associated ITP (HIV-ITP),
and later developed an acute hemorrhagic stroke. This patient showed
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a remarkable clinical response to the re-initiation of the antiretroviral
therapy (ART) in combination with plasma exchange therapy, and was
able to achieve a complete recovery without developing significant
chronic renal or neurological sequelae.

Case Presentation
A 16-year old African American HIV-infected female presented to
the emergency department (ED) with three days history of continuous
oral bleeding after biting her lip. She also reported gingival bleeding
after brushing her teeth and two small bruises on her forearm and
thigh in the preceding 3 weeks. She denied any joint pain or swelling,
fever, diarrhea, melena, or hemoptysis. The patient was prescribed
ART with zidovudine (AZT) and lamivudine (3TC) (as (Combivir®),
plus tenofovir disoproxil fumarate (TDF) and lopinavir (Kaletra®). On
presentation to the ED, she reported significant non-adherence to ART.
The patient past medical history revealed a previous episode of anemia
and symptomatic (petechiae) thrombocytopenia (10×109/L) at the age
of 13 years treated with steroids. During this episode, after extensive
evaluation including bone marrow aspiration, she was diagnosed
with perinatally acquired HIV-1 infection, Center for Disease Control
(CDC) category B3. Her mother was diagnosed with HIV-1 infection
a few years before. Past medical history also included febrile seizures,
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recurrent otitis media, bacterial endocarditis, and pneumonia. At the
time of HIV diagnosis her CD4+ cell count was 160 cells/mm3 (11%)
and the HIV RNA viral load (VL) was 36,700 copies/ mL with no
resistance-associated mutations on HIV-1 phenotype. The initial ART
included stavudine (d4T), lamuvidine (3TC) and lopinavir/ritonavir
(Kaletra®). With intermittent adherence to the ART, her CD4+ cell
count remained fluctuant in the range of 12-30%, and her HIV-1 RNA
VL ranged between 1,049 to 99,765 copies/mL. Eighteen months after
initiation of ART the patient had a repeat episode of asymptomatic
thrombocytopenia (33×109/L) treated with a single dose of RhoD
immune globulin (Ig) (WinRho®, Cangene Corporation; Winnepeg,
Canada). Except for this single episode, her platelets remained in the
range of 148-262×109/L. Four months prior to her presentation to
the ED, the hemoglobin (Hb) and hematocrit (Hct) were 11.5 g/dL
and 34.9% respectively, with a platelet count of 178×109/L. Due to the
development of 184V HIV mutation six months prior to her visit to the
ED, the ART was changed as described above. On initial presentation to
the ED, the patient was afebrile, tachycardic (90 beats/min), tachypneic
(28 respirations/min) with a mildly elevated blood pressure (132/76
mm Hg). Physical examination was notable for a bite wound on the
lower lip that was oozing blood. Small petechiae (4 mm) were noted on
the forearms and a slightly larger purpura (50 mm) on the thighs. Aside
from bilateral cervical lymphadenopathy, the remainder of the physical
exam was normal. Laboratory studies revealed severe normocytic
anemia and thrombocytopenia, elevated aspartate aminotransferase
(AST), elevated lactate dehydrogenase (LDH) and total bilirubin, with
a normal coagulation profile (Table 1). Peripheral smear displayed
schistocytes, polychromasia, anisocytosis, and poikilocytosis. A
urinalysis demonstrated proteinuria and hemoglobinuria; a pregnancy
test was negative.
The patient received a transfusion with packed red blood cells
(PRBC) and given the history of the HIV-associated ITP responding to
Test

Patient Values

Reference

5.2 g / dL

(10.8 – 13.3)

Hematocrit (Hct)

15.8 %

(33.4-40.4)

Platelet count

3 K / uL

(194-345)

Schistocytes

3+

None

105.9 K / uL

(41.6-65.1)

5.32%

(0.9-1.49)

(LDH) 1173 IU / L

(117-213)

Hemoglobin (Hb)

Automated absolute reticulocytes
Automated reticulocyte count
Lactate dehydrogenase
Haptoglobin

< 7 mg / dL

(43-212)

Prothrombin time (PT)

13.4 sec

(11.1-14.5)

Activated partial thromboplastin time
(aPTT)

32.7 sec

(23.1-35.0)

1.06

(0.80-1.11)

1.5 mg / dL

(< 0.8)

Blood International Normalized Ratio (INR)
Total bilirubin
AST

101 U / L

(0-26)

ALT

47 U / L

(19-49)

Blood urea nitrogen

14 mg / dL

(7-21)

Creatinine

0.4 mg / dL

(0.5-1.1)

CD4+ count
CD4+ %
HIV Viral Load
Total protein
Urine Blood
Urine RBC

299 cells

(>350)

12%

(>25%)

245,874 copies / mL

(< 48)

2+

None

3+

None

1 per HPF

(< 3)

Table 1: Initial Laboratory Findings.
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Figure 1: Emergent head CT demonstrating the larger of two frontoparietal
hemorrhages.

Rho D Ig, was started on daily infusions of intravenous immunoglobulin
G (IVIg) for initial diagnosis of immune thrombocytopenic purpura
(ITP) associated with HIV-1 infection. This treatment lead to an increase
in platelets count to 12×109/L within 24 hours. Platelet transfusion was
reserved for signs of neurological deterioration and the prescribed ART
was restarted. On hospital day (HD) #4, the patient acutely developed
altered mental status with aphasia. An emergent head CT showed left
hemispheric cerebral hemorrhages with mass effect and surrounding
edema (Figure 1). The patient was transferred to the pediatric intensive
care unit (PICU), where she experienced a generalized tonic-clonic
seizure requiring intubation. At the time her Hb and Hct were 5.9 g/
dL and 17.2%, respectively with a platelet count of 18×109/L and an
LDH of 2087 IU/L. Following an emergent transfusion of 4 random
donor equivalent apheresis platelets (which led to platelet count of
43×109/L within 24 hours) and PRBCs, (given initially through the
COBE Spectra cell separator (Terumo BCT, Lakewood, CO), plasma
exchange with fresh frozen plasma (FFP) replacement was initiated.
A total of 7 plasma exchange procedures were performed with 1.3-1.9
plasma volumes exchanged per procedure until near normalization of
LDH and normal platelet count for two days. While undergoing plasma
exchange, she was transfused twice with PRBCs, and was treated
with methylprednisolone and levetiracetam. Two days after the PICU
admission her neurological status improved and she was extubated.
Though she initially demonstrated right facial and upper extremity
weakness, these symptoms resolved by the time of discharge on HD #16
and she displayed no residual neurologic damage, except for seizures
well controlled with anticonvulsant therapy. A new ART regimen with
AZT/3TC (Combivir®), TDF, and efavirenz (EFV) was started on HD
#8. Interestingly, her HIV RNA VL decreased dramatically as a result
of plasma exchange, and the decrease VL correlated with an increase
in platelet count and a decrease in plasma LDH levels (Figure 2). A test
for ADAMTS13 levels (performed at the Blood Center of Wisconsin
prior to the start of plasma exchange) revealed an activity of < 5%
(reference interval ≥ 67%), confirming the diagnosis of TTP despite no
detectable inhibitory antibody (0.4 inhibitor units, reference interval ≤
0.4). The repeat test on HD # 10, after 7 plasma exchange procedures,
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Figure 2: (A) Platelets (green line) and LDH (blue line) levels during hospital
course; the light blue and light green areas indicate the reference interval for
LDH and platelet count respectively, black bars indicate plasma exchange
procedures; the pink bar indicates platelet transfusion; the black arrows and
numbers demonstrate separate HIV-RNA viral loads in copies/mL; the asterisk
(*S) identifies the stroke event.

showed a significant increase in ADAMTS13 activity to 63%, and the
inhibitory antibody test was not repeated. After discharge, the patient’s
adherence to ART significantly improved, leading to undetectable
HIV RNA levels (VL < 48 copies/mL) and a stable increase in CD4+
to 31% (563 cells/mm3) within 16 weeks. She suffered no permanent
renal or neurologic deficits, except for seizure disorder well controlled
with anticonvulsants, and maintained undetectable HIV-1 RNA VL
and stable CD4+ cell counts 52 weeks after the start of the new ART
regimen. Informed consent to report this case was obtained from the
patient and her family and approved by the IRB at Children’s National
Medical Center.

Discussion
This case illustrates the clinical dilemma generated by an adolescent
female who presented with an acute episode of severe thrombocytopenia
accompanied with MAHA and a past medical history of HIV-ITP.
Because MAHA is not present in HIV-ITP [4], two different diseases
were considered in the differential diagnosis. Initially, the patient did
not present fever, neurological symptoms, or renal failure, therefore
the diagnosis of HIV-ITP was prioritized, while in the mean time,
additional tests were done to determine the etiology of the MAHA. In
subsequent days, the patient developed neurological symptoms caused
by a cerebral hemorrhage, and a decreased ADAMTS13 activity (<5
%), confirmed the diagnosis of HIV-TTP. The patient had an excellent
clinical response to plasma exchange therapy, in agreement with the
outcome of previous adult cases of HIV-TTP [4,11,12]. These studies
recommend the prompt initiation/re-initiation of ART in parallel
with plasma exchange therapy to accelerate the remission of HIVTTP [4,11,12] and prevent lethal complications [13-16]. In summary,
this case highlights the challenges and importance of making an early
identification and treatment of children with HIV-TTP.
Primary ITP, named recently “immune thrombocytopenia”
to emphasize the immune mediated mechanism of the disease, is
defined as isolated thrombocytopenia with normal bone marrow and
absence of other causes of low platelets [17,18]. It involves acquired
megakaryocytic thrombocytopenia with the shortened life of platelets
due to immunological damage [17,18]. Secondary ITP, include all
forms of immune thrombocytopenias that are due to an underlying
disease, including HIV-1 infection [17]. The distinction between
primary and secondary ITP forms is clinically relevant, because they
have different natural history, pathogenesis, and treatment [18]. HIVITP, is treated effectively with ART, short-term corticosteroids, IVIg
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and anti-D [17]. In our case, the patient received ART and IVIg, and
the platelet count increased from 3×109/L to 18×109/L in a few days
before plasma exchange therapy was initiated. This response may argue
in favor of the diagnosis of ITP, however the rise in platelet count
was inadequate to prevent the intracranial bleeding, and cannot be
considered a successful response according to recent guidelines [17]. In
contrast, the remarkable clinical response to plasma exchange therapy,
strongly suggests that clinical symptoms were predominately caused by
HIV-TTP. Interestingly, very few cases of HIV-associated TTP and ITP
occurring in the same patients have been reported in the literature [19].
All these cases were adult patients, and the diagnosis of ITP preceded
or followed the onset of TTP by years or months [19]. To the best of
our knowledge, only one adult patient was described in whom both,
ITP and TTP, were present simultaneously [19]. In this case, the platelet
count did not improve during the plasma exchange treatment. Thus,
although we cannot exclude the possibility that both diseases were
present simultaneously in our patient, the dramatic response to plasma
exchange therapy, and the clinical response of the only case reported in
the literature [19], suggests that this possibility is unlikely.
Thrombotic microangiopahties (TMA) are characterized by the
involvement of widespread occlusive microvascular thromboses
resulting in thrombocytopenia, (MAHA), and variable symptoms
of end-organ ischemia. Different primary or acquired etiologies
contribute to the spectrum of TMA in HIV-infected patients, including
disseminated intravascular coagulopathy (DIC). Children develop
typical and atypical forms of HUS secondary to infectious pathogens
(E. coli 0157:H7, Salmonella, Campylobacter, and Pneumococcus spp)
[20-22], and underlying genetic defects such as deficiency in certain
complement factors or proteins associated with processing the ultralarge thrombogenic multimers of vWF [23-25]. In a previous study, we
reported two fatal pediatric cases of atypical HIV-HUS of unknown
etiology [3]. Thus, the pathogenesis of HIV-HUS is multifactorial, and
it is not always possible to identify the primary factors triggering these
events. The patient described in this report, had no history of recent
gastrointestinal illness or family history consistent with any primary
defect that could trigger HUS. DIC is sometimes included in the TMA
spectrum, as its widespread thrombus formation can lead to MHA.
On peripheral smear, DIC and TTP can be nearly indistinguishable,
with both resulting in an overall thrombocytopenia. The hallmark
consumptive coagulopathy with associated coagulation profile
abnormalities, however, was missing in our patient [26,27]. Due to the
combination of MAHA, thrombocytopenia, neurological symptoms,
and decreased ADAMTS13 activity [24,25], our patient most closely fit
the definition of TTP. The activity of ADAMTS13 increased from < 5%
to 63% after 10 days of treatment with ART and seven plasma exchange
procedures, in correlation with an excellent clinical recovery. Moreover,
her underlying HIV diagnosis is consistent with reports of a unique role
of HIV-1 in the pathogenesis of this disease.
Hereditary forms of TTP (e.g. Upshaw-Schulman syndrome)
are due to a genetic deficiency of the metalloproteinase ADAMTS13
[28]. The ADAMTS13 deficiency leads to the accumulation of high
molecular weight vWF multimers, which in turn, form platelet rich
clots that cause TMA lesions and microangiopathic hemolytic anemia.
In acquired forms of TTP, reduced protease activity may be caused
by the production of an autoimmune antibody against ADAMTS13;
however, these autoantibodies cannot always be detected [29]. A recent
summary presented at the 2012 American Society for Apheresis (ASFA)
Consensus Conference on Classification, Diagnosis, Management, and
Future Research in TTP showed that the autoantibody is present in
idiopathic disease in 51 to 93% of cases [30]. Not all adults with HIV-
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TTP reported in the literature however, show a significant decrease
in the activity of ADAMTS13 [4,9,31,32]. The number of cases varies
depending on the definition of HIV-TTP used in each study. Thus,
we cannot be sure that all patients with HIV-HUS or other causes of
MAHA were excluded from these studies. Alternatively, HIV-1 can play
a unique role in the pathogenesis of HIV-TTP by causing widespread
endothelial damage from direct viral or cytokine-mediated cell injury
[4,9,32]. These changes cause the release of vWF triggering a localized
coagulation cascade mainly in the renal and brain microvasculature,
[4,31,32]. In our case, the patient’s decrease in ADAMTS13 activity
was not associated with a detectable specific inhibitory antibody.
However, considering that the ADMATS 13 activity only increased
to 63% during recovery, we cannot exclude the presence of low
inhibitor levels that were not detected with the test used. Repeat
plasma exchange treatments led to the resolution of TTP through
replenishing of the ADAMTS13 activity and reversing the platelet
clot formation and platelet consumption (Figure 2). The rise in the
platelet count in our patient was associated with a significant drop in
HIV-1 RNA VL attributable to the re-initiation of ART and possibly,
to the physical removal of viruses and circulating cytokines through
the plasma exchange therapy. It is tempting to speculate that the
removal of inflammatory cytokines and HIV virions through plasma
exchange, could have reduced the endothelial damage and secondary
release of vWF release [4,9,32]. Nonetheless, the more sustainable
increase in platelet count was observed following the initiation of ART.
This is consistent with other reports of HIV-associated TTP, where
patients’ improvement was shown to be directly related to the virologic
suppression [4-6,9,11,12,31,32]. The ability of ART to down-regulate
inflammatory molecules on endothelial cells may play an additional
role in this process [4,9,33-35]. In summary, all successful therapies
of HIV-TMA lesions require the underlying treatment of the HIVinfection [4,9,32].

bleeding [36]. However, a recent review of the Oklahoma TTP-HUS
Registry, based on 382 consecutive patients, concluded that the evidence
that platelet transfusions are harmful for patients with TTP is uncertain
[30,37], in particular, if given simultaneously with the plasma exchange
therapy [37,38]. Thus, all children with hematological complications
of HIV and questionable adherence to ART need to be monitored
closely as TMA lesions can develop in a relatively short period of time.
Thrombocytopenia in the presence of schistocytes, elevated LDH and
total bilirubin, decreased haptoglobin, and hemoglobinuria, are useful
laboratory markers to identify a thrombotic process with microvascular
destruction of erythrocytes. However all these changes are not always
present or detected during the initial stages of TTP. In conclusion, the
excellent recovery of this pediatric patient who suffered a hemorrhagic
stroke, demonstrates the necessity of establishing a rapid diagnosis and
treatment of HIV-TTP in children, and to sustain a long term reduction
of the viral load in these patients.

Previous studies done before effective ART regimens were
established, reported a poor prognosis for patients with HIV-TTP
or TMA, with few patients surviving longer than 24 months [2-7].
Subsequent studies showed much better outcomes, suggesting that the
prognosis may be more closely related to the stage of HIV-infection
and severity of immunosuppression at the time of diagnosis, rather
than the TTP event per se. More recent studies in adults indicate that
approximately 80% of the HIV-infected patients with TTP can have
a successful response to ART in combination with plasma exchange
[4,7,12]. Moreover, it appears that patients with primary neurological
symptoms characteristic of classic TTP, like in our case, are more
responsive to plasma exchange [4].

5. Miller RF, Scully M, Cohen H, Roedling S, Starke R, et al. (2005) Thrombotic
thrombocytopaenic purpura in HIV-infected patients. Int J STD AIDS 16: 538542.

Finally, it is worth mentioning that many AIDS-related disorders or
viral infections associated with HIV-1 can cause symptoms similar to
HIV-TTP. Furthermore, these patients may have ongoing renal and/or
neurological symptoms, affecting the standard clinical criteria used to
make an early diagnosis, or the decision when to initiate plasma exchange
therapy. HIV associated anemia, neutropenia and/or thrombocytopenia
are frequently seen at the time of the initial HIV-1 diagnosis and usually
resolve with effective ART, unless they are associated with antiretroviral
therapy. As discussed before, based on a past medical history of HIVITP, the presence of severe thrombocytopenia in combination with
other laboratory features of TMA may be overlooked. Another clinical
dilemma in patients with HIV-TTP, is the decision to give platelet
transfusions to patients with severe thrombocytopenia who need a
catheter placement or other invasive procedures. Early complications
of platelet transfusions given to patients with TTP resulted in the
recommendation to avoid this treatment except for life-threatening
J AIDS Clin Res
ISSN: 2155-6113 JAR an open access journal
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